FACTORS ASSOCIATED WITH PNEUMOCYSTIS-CARINII PNEUMONIA IN WEGENERS GRANULOMATOSIS

被引:70
作者
GODEAU, B
MAINARDI, JL
ROUDOTTHORAVAL, F
HACHULLA, E
GUILLEVIN, L
DU, LTH
JARROUSSE, B
REMY, P
SCHAEFFER, A
PIETTE, JC
机构
[1] HOP CLAUDE HURIEZ,UNITE EVALUAT CLIN & BIOSTAT,LILLE,FRANCE
[2] HOP CLAUDE HURIEZ,SERV NEPHROL,LILLE,FRANCE
[3] HOP CLAUDE HURIEZ,SERV MED INTERNE,LILLE,FRANCE
[4] HOP AVICENNE,SERV MED INTERNE,F-93009 BOBIGNY,FRANCE
[5] HOP LA PITIE SALPETRIERE,SERV MED INTERNE,PARIS,FRANCE
关键词
D O I
10.1136/ard.54.12.991
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-To determine the factors associated with the occurrence of Pneumocystis carinii pneumonia (PCP) in Wegener's granulomatosis (WG). Methods-We retrospectively compared a group of 12 patients with WG and PCP (PCP group), with 32 WG patients without PCP followed over the same period in the same centres (control group). Results-The mean delay of onset of PCP after the start of the immunosuppressive therapy was 127 (SD 128) days. Before treatment, the clinical and biological features of the two groups were similar, except for the mean lymphocyte count which was lower in the PCP group than in the control group (1060/mm(3) v 1426/mm(3); p = 0.04). During treatment, both groups were lymphopenic. There was a significant difference between the lowest Creteil, France absolute lymphocyte count in each group (244/mm(3) in the PCP group v 738/mm(3) in the control group; p = 0.001). During the first three months of treatment, the lymphocyte count was less than 600/mm(3) at least once in 10 of the 12 patients in the PCP group and in 11 of the 32 patients in the control group (p<0.01). The mean cumulative dose of cyclophosphamide was greater in the PCP group than in the control group at the end of both the second (1.55 mg/kg/day v 0.99 mg/kg/day; p = 0.05) and the third (1.67 mg/kg/day v 0.97 mg/kg/day; p = 0.03) months. However, in multivariate analysis, the only two factors independently and significantly associated with the occurrence of PCP were the pretreatment lymphocyte count (p=0.018) and the lymphocyte count three months after the start of the immunosuppressive treatment (p = 0.014). Conclusions-The severity of lymphocytopenia before and during immunosuppressive treatment is the factor best associated with PCP in WG.
引用
收藏
页码:991 / 994
页数:4
相关论文
共 14 条
[1]   INFECTIOUS COMPLICATIONS OF CYCLOPHOSPHAMIDE TREATMENT FOR VASCULITIS [J].
BRADLEY, JD ;
BRANDT, KD ;
KATZ, BP .
ARTHRITIS AND RHEUMATISM, 1989, 32 (01) :45-53
[2]   THE TREATMENT OF WEGENERS GRANULOMATOSIS WITH TRIMETHOPRIM SULFAMETHOXAZOLE - ILLUSION OR VISION [J].
DEREMEE, RA .
ARTHRITIS AND RHEUMATISM, 1988, 31 (08) :1068-1072
[3]  
GODEAU B, 1994, J RHEUMATOL, V21, P246
[4]   THE TREATMENT OF WEGENERS GRANULOMATOSIS WITH GLUCOCORTICOIDS AND METHOTREXATE [J].
HOFFMAN, GS ;
LEAVITT, RY ;
KERR, GS ;
FAUCI, AS .
ARTHRITIS AND RHEUMATISM, 1992, 35 (11) :1322-1329
[5]   WEGENER GRANULOMATOSIS - AN ANALYSIS OF 158 PATIENTS [J].
HOFFMAN, GS ;
KERR, GS ;
LEAVITT, RY ;
HALLAHAN, CW ;
LEBOVICS, RS ;
TRAVIS, WD ;
ROTTEM, M ;
FAUCI, AS .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (06) :488-498
[6]   TREATMENT OF WEGENERS GRANULOMATOSIS WITH INTERMITTENT HIGH-DOSE INTRAVENOUS CYCLOPHOSPHAMIDE [J].
HOFFMAN, GS ;
LEAVITT, RY ;
FLEISHER, TA ;
MINOR, JR ;
FAUCI, AS .
AMERICAN JOURNAL OF MEDICINE, 1990, 89 (04) :403-410
[7]  
JARROUSSE B, 1993, CLIN EXP RHEUMATOL, V11, P615
[8]   PNEUMOCYSTIS-CARINII PNEUMONIA - THERAPY AND PROPHYLAXIS [J].
KOVACS, JA ;
MASUR, H .
JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (01) :254-259
[9]   PNEUMOCYSTIS-CARINII PNEUMONIA - A COMPARISON BETWEEN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME AND PATIENTS WITH OTHER IMMUNODEFICIENCIES [J].
KOVACS, JA ;
HIEMENZ, JW ;
MACHER, AM ;
STOVER, D ;
MURRAY, HW ;
SHELHAMER, J ;
LANE, HC ;
URMACHER, C ;
HONIG, C ;
LONGO, DL ;
PARKER, MM ;
NATANSON, C ;
PARRILLO, JE ;
FAUCI, AS ;
PIZZO, PA ;
MASUR, H .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (05) :663-671
[10]   THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY 1990 CRITERIA FOR THE CLASSIFICATION OF WEGENER GRANULOMATOSIS [J].
LEAVITT, RY ;
FAUCI, AS ;
BLOCH, DA ;
MICHEL, BA ;
HUNDER, GG ;
AREND, WP ;
CALABRESE, LH ;
FRIES, JF ;
LIE, JT ;
LIGHTFOOT, RW ;
MASI, AT ;
MCSHANE, DJ ;
MILLS, JA ;
STEVENS, MB ;
WALLACE, SL ;
ZVAIFLER, NJ .
ARTHRITIS AND RHEUMATISM, 1990, 33 (08) :1101-1107